Skip to main content

View Resource

Published

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.
Rumyantsev A. eClinicalMedicine 2025;:https://doi.org/10.1016/j.eclinm.2025.103349.
[Authorized COVID-19 vaccines require boosters for continued protection; however, the lack of cross-platform compatible boosters creates practical challenges to keeping populations protected. In a pivotal Phase 3 study, UB-612 demonstrated the potential for broad use as a cross-platform heterologous booster, restoring protective immunity in adults previously vaccinated with mRNA, adenovirus-vectored, or inactivated virus-based COVID-19 vaccines.]
Freely available online
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Population Health
Staff Groups
Immunisation
Public Health Doctor
Public Health Specialist